NCT03243877 is a clinical trial of MammoAlert Screening Test in Breast Cancer, sponsored by POC Medical Systems, Inc..

Who is sponsoring NCT03243877?

NCT03243877 is sponsored by POC Medical Systems, Inc..

What drugs are being tested in NCT03243877?

Interventions in NCT03243877: MammoAlert Screening Test.

What condition does NCT03243877 study?

NCT03243877 studies Breast Cancer.

Is NCT03243877 still recruiting?

NCT03243877 is currently status unknown. Last updated 11 April 2018.

Last reviewed 2018-04-11 · How we verify

NCT03243877

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Performance of MammoAlert™, Point of Care System, for the Screening of Breast Cancer in Women 18 Years of Age or Older

Status unknown Last updated 11 April 2018

What this trial tests

trial testing MammoAlert Screening Test in Breast Cancer in 2,458 participants. Status unknown.

Timeline

17 June 2017

Primary endpoint
26 November 2017

31 August 2018

Quick facts

Lead sponsor	POC Medical Systems, Inc.
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	2,458
Start date	17 June 2017
Primary completion	26 November 2017
Estimated completion	31 August 2018
Sites	7 locations across India

Drugs / interventions tested

MammoAlert Screening Test

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

POC Medical Systems, Inc.

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

POC Medical Systems has developed a Point of Care system for the screening of breast cancer in the general population. Via a proprietary algorithm, the MammoAlert™ is expected to determine breast cancer's risk level for a subject by identifying the presence in plasma of known biomarkers. The present study aims to determine the Sensitivity and Specificity of the test in plasma samples of subjects of whom the status vis-à-vis breast cancer is known.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03243877 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by POC Medical Systems, Inc.
Last refreshed: 11 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03243877.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing